» Articles » PMID: 32012106

Evaluation of Patterns of Presentation, Practice, and Outcomes of Upper Tract Urothelial Cancer: Protocol for an Observational, International, Multicenter, Cohort Study by the Clinical Research Office of the Endourology Society

Overview
Journal JMIR Res Protoc
Publisher JMIR Publications
Specialty General Medicine
Date 2020 Feb 4
PMID 32012106
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Available guidelines on the management of upper tract urothelial carcinoma (UTUC) are restricted due to the lack of strong evidence-based recommendations. Adequate, well-powered randomized trials are missing due to the rarity of the disease. To overcome this problem, we need alternative study designs to provide generalizable data.

Objective: The primary aim of this registry is to provide a real-world overview on patterns of presentation and management of UTUC. Secondary objectives include comparison of outcomes of different treatments and tumor stages and evaluation of compliance with the current European Association of Urology recommendations for UTUC.

Methods: For this observational, international, multicenter, cohort study, clinical data of consecutive patients suspected of having UTUC, irrespective of type of management, will be prospectively collected up to 5 years after inclusion. Data on the patterns of presentation, diagnostics, and treatment as well as short-, mid-, and long-term oncological and functional outcomes will be analyzed. Possible associations between variables, basal characteristics, and outcomes will be tested by multivariable analyses. The methodology will address potential sources of bias and confounders.

Results: The registry was initiated in November 2014 after obtaining institutional review board approval. Data collection started in December 2014. At the time of submission of this manuscript, 2451 patients from 125 centers from 37 countries were included. Inclusion of patients will be closed 5 years after initiation of the registry. Quality checks will be performed centrally with continuous communication and feedback with the centers to ensure accuracy. The first results are expected in the first trimester of 2020.

Conclusions: This large observational prospective cohort will generate landmark "real-world" data and hypotheses for further studies. We expect these data to optimize the management of UTUC, provide insights on harms and benefits of treatment, and serve as quality control.

Trial Registration: ClinicalTrials.gov NCT02281188; https://clinicaltrials.gov/ct2/show/NCT02281188.

International Registered Report Identifier (irrid): DERR1-10.2196/15363.

Citing Articles

Chronic renal impairment predicts oncological outcomes in UTUC patients undergoing RNU.

Wong C, Liu K, Zhao H, Sabuncu K, Horuz R, Albayrak S BMC Urol. 2024; 24(1):250.

PMID: 39538261 PMC: 11559099. DOI: 10.1186/s12894-024-01627-0.


Impact of Pre-Operative Ureteroscopy on Bladder Recurrence Following Nephroureterectomy for UTUC.

Wong C, Ko I, Leung D, Liu K, Zhao H, Alvarez-Maestro M Cancers (Basel). 2024; 16(15).

PMID: 39123411 PMC: 11311632. DOI: 10.3390/cancers16152683.


Impact of Adjuvant Gemcitabine Containing Chemotherapy Following Radical Nephroureterectomy for Patients with Upper Tract Urothelial Carcinoma: Results from a Propensity-Score Matched Cohort Study.

Hongda Z, Kang L, Ng C, de la Rosette J, Laguna P, Gontero P Bladder Cancer. 2024; 9(3):217-226.

PMID: 38993186 PMC: 11181833. DOI: 10.3233/BLC-230041.


Unveiling the challenges of UTUC biopsies and cytology: insights from a global real-world practice study.

Baard J, Cormio L, Dasgupta R, Maruzzi D, Rais-Bahrami S, Serrano A World J Urol. 2024; 42(1):177.

PMID: 38507109 PMC: 10954852. DOI: 10.1007/s00345-024-04866-w.


Impact of previous malignancy at diagnosis on oncological outcomes of upper tract urothelial carcinoma.

Zhao H, Liu K, Giannakopoulos S, Yuruk E, De Naeyer G, Alvarez-Maestro M BMC Urol. 2023; 23(1):49.

PMID: 36991375 PMC: 10061966. DOI: 10.1186/s12894-023-01206-9.


References
1.
Marchioni M, Primiceri G, Cindolo L, Hampton L, Grob M, Guruli G . Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: a systematic review and meta-analysis. BJU Int. 2017; 120(3):313-319. DOI: 10.1111/bju.13935. View

2.
Peyronnet B, Seisen T, Dominguez-Escrig J, Bruins H, Yuan C, Lam T . Oncological Outcomes of Laparoscopic Nephroureterectomy Versus Open Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An European Association of Urology Guidelines Systematic Review. Eur Urol Focus. 2017; 5(2):205-223. DOI: 10.1016/j.euf.2017.10.003. View

3.
Guyatt G, Oxman A, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650):924-6. PMC: 2335261. DOI: 10.1136/bmj.39489.470347.AD. View

4.
Liu F, Guo W, Zhou X, Ding Y, Ma Y, Hou Y . Laparoscopic versus open nephroureterectomy for upper urinary tract urothelial carcinoma: A systematic review and meta-analysis. Medicine (Baltimore). 2018; 97(35):e11954. PMC: 6393120. DOI: 10.1097/MD.0000000000011954. View

5.
Kuroda K, Asakuma J, Horiguchi A, Kawaguchi M, Shinchi M, Masunaga A . Chronic kidney disease and positive surgical margins as prognosticators for upper urinary tract urothelial carcinoma patients undergoing radical nephroureterectomy. Mol Clin Oncol. 2019; 10(5):547-554. PMC: 6449878. DOI: 10.3892/mco.2019.1829. View